RxDoctor Payments Data

Erica Austin, DO

Clinical Neurophysiology · Traverse City, MINPI 1477715076

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $913 of the $1,029 with a category attached, or 88.7%. 13 manufacturers reported payments, led by AbbVie at 34.2% of the total. Reporting peaked in 2024 at $309 and has fallen 72.8% since, to $84 in 2025.

$1,029in general payments, 2019–2025

Across 30 payments — averaging $34.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$352
  • Neurelis, Inc.$257
  • Eisai Inc.$122
  • Johnson & Johnson$84
  • Novartis$47
  • Sanofi$36
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$91389%
  • Education$11611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$46,242
Medicare patients
273
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine42$290,136
EpidiolexCannabidiol (Cbd)39$216,192
XcopriCenobamate69$77,050
Lacosamide240$40,374
Aimovig AutoinjectorErenumab-Aooe29$24,749
Levetiracetam495$21,564
NayzilamMidazolam23$17,963
Emgality PenGalcanezumab-Gnlm14$16,105
ValtocoDiazepam18$13,482
Carbidopa-LevodopaCarbidopa/Levodopa131$8,682
Methsuximide13$5,945
Lamotrigine197$5,766
Clobazam62$5,630
Zonisamide115$4,761
Gabapentin184$4,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Nayzilam$23$17,96323 claims
Neurelis, Inc.Valtoco$257$13,48218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →